Ultima-Turinabol 20 – Ultima Pharma Ultima Pharmaceuticals: Compound Profile
Ultima-Turinabol 20 is a synthetic anabolic-androgenic steroid manufactured by Ultima Pharmaceuticals, containing 4-chlorodehydromethyltestosterone as the active pharmaceutical ingredient. This chlorinated derivative of methandrostenolone demonstrates unique pharmacological properties in laboratory studies, particularly in research examining anabolic pathways without significant estrogenic conversion. Researchers at Stroid UK Shop investigate this compound for its distinctive molecular structure that incorporates a chlorine atom at the 4-position, preventing aromatization to estrogen metabolites in enzymatic assays.
Laboratory Applications
Scientific investigations focus on this compound’s selective anabolic properties in cellular models, where researchers examine protein synthesis enhancement without concurrent water retention mechanisms. Laboratory studies evaluate its binding affinity to androgen receptors and subsequent transcriptional activation pathways. Research protocols often compare outcomes with other compounds available through our Turinabol oral steroids category. Advanced researchers studying comparative anabolic mechanisms may cross-reference findings with SARMs research or investigate synergistic pathways alongside peptides in comprehensive metabolic studies.
Molecular Specifications
| Active Ingredient | 4-chlorodehydromethyltestosterone |
|---|---|
| Concentration | 20mg per tablet |
| Chemical Formula | C20H27ClO2 |
| Molecular Weight | 334.88 g/mol |
| CAS Number | 2446-23-3 |
| Manufacturer | Ultima Pharmaceuticals |
| Storage Requirements | Room temperature, dry environment |
| Analytical Testing | HPLC verified purity |
Research Compliance
Ultima-Turinabol 20 is manufactured exclusively for in-vitro laboratory research applications and is not approved for human consumption, therapeutic use, or any purpose outside controlled scientific investigation. Researchers must maintain appropriate laboratory protocols and regulatory compliance when conducting studies with this compound. All research should be performed under proper institutional oversight with appropriate safety measures and documentation.
